Clinical trial · Interventional
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
Resistance Exercise Combined With Protein Supplementation for Skeletal Muscle Mass in People With Pancreatic Cancer Undergoing Chemotherapy: The RE-BUILD Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to determine whether a virtually supervised resistance exercise (RE) intervention combined with protein supplementation (PS) is feasible in pancreatic cancer patients initiating chemotherapy and if it will improve skeletal muscle mass. The names of the study interventions involved in this study are: * Resistance training and protein supplement intake (RE + PS) * Resistance training (RE) * Attention control (AC), home-based stretching
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Attention Control (AC | Behavioral | — | UNRESOLVED |
| Resistance Training (RT) | Behavioral | — | UNRESOLVED |
| Resistance Training (RT) and Protein Supplementation (PS) | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Resistance Training (RT) and Protein Supplementation (PS)
- description
- Participants will be randomly assigned to the Resistance Training (RT) and Protein Supplementation (PS) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week with daily protein supplementation for the duration of their chemotherapy with a maximum of 16-weeks of exercise. Exercises will be tailored to the participants' fitness levels. Sessions will last \~60 minutes including 5-minute warm-up and 5-minute cool-down. Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.
- interventionNames
- Behavioral: Resistance Training (RT) and Protein Supplementation (PS)
- type
- EXPERIMENTAL
- label
- Resistance Training (RT)
- description
- Participants will be randomly assigned to the Resistance Training (RT) group and receive virtually (Zoom) supervised home-based exercise program 3-days a week. Exercises will be tailored to the participants' fitness levels. Participants will also have two body composition scans using CT over the span of chemotherapy treatment (maximum 16 weeks) and approximately 3 hours of evaluation of testing on 3 occasions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Non-metastatic pancreatic cancer patients initiating neoadjuvant chemotherapy. * Ability to understand and the willingness to sign a written informed consent document. * Over the age of 18 years; children under the age of 18 will be excluded due to rarity of disease. * Speak English or Spanish. * Able to provide physician clearance to participate in the exercise program. * Able to initiate a supervised exercise program (free from any cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity). * Currently participate in less than or equal to 60 minutes of structured moderate or vigorous exercise/week. * Does not smoke (no smoking during previous 12 months). * Willing to travel to DFCI for assessments. Exclusion Criteria: * Patients should not have any uncontrolled illness including ongoing or active infection, uncontrolled diabetes, hypertension or thyroid disease. * Patients may not be receiving any other investigational agents. * Patients with other active malignancies are ineligible for this study. * Patients with metastatic disease. * History of any musculoskeletal, cardiorespiratory or neurological diseases that preclude the participation in exercise. * Patients expected to receive other cancer directed treatments during the study and assessment period. * Participates in more than 60 minutes of structured moderate or vigorous exercise/week. * Currently smokes. * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study. * Is unable to travel to DFCI for assessments. * Patients who are pregnant due to the unknown effects of exercise on the developing fetus.
References
Publications (0)
Data not yet available